Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 23, 2024 17:00 ET
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with...
A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
May 22, 2024 10:23 ET
|
Trial Equity
Trial Equity and Miller Tanner Associates are partnering to expand clinical trial participation to address the gap in diversity.
YPrime Transforms Endocrinology and Autoimmune Trials through New Glucometer and eCOA Integrated Functionality
May 21, 2024 08:00 ET
|
Y-Prime, LLC
YPrime's new glucometer/eCOA functionality offers a patient-centric, intuitive, and connected experience to clinical trial participants.
HeartFlow's Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study
May 15, 2024 12:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its...
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
April 30, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
April 22, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal...
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
March 27, 2024 23:43 ET
|
Indegene Inc
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease
March 26, 2024 14:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in AI-driven healthcare technology, today announced the launch of the DECIDE Registry, the largest prospective...